Curis Lifesciences IPO Subscription Status: IPO Subscribed 16.45 Times | Day 3

Ahmedabad, November 11: Curis Lifesciences IPO has been subscribed 16.45 times overall so far on Day 3. As of 12:50 PM, the Curis Lifesciences IPO had received bids for 2,35,78,000 shares against 14,33,000 shares on offer. The Non-Institutional Investors (NIIs) category led the demand, subscribing 25.40 times with bids for 78,22,000 shares against 3,08,000 shares on offer. This was followed by the Qualified Institutional Buyers (QIBs), who subscribed 20.09 times, placing bids for 82,18,000 shares against 4,09,000 shares on offer. Meanwhile, the Retail Investors category was subscribed 10.53 times, with 75,38,000 bids received against 7,16,000 shares on offer.

Key Details About Curis Lifesciences IPO

Curis Lifesciences IPO is a book build issue of ₹27.52 crores. The issue is entirely a fresh issue of 0.22 crore shares of ₹27.52 crore. Curis Lifesciences IPO bidding opened for subscription status on November 7, 2025, and will close today, on November 11, 2025. The share allotment for the Curis Lifesciences IPO is expected to be finalised on November 12, 2025. Curis Lifesciences IPO will list on NSE SME with a tentative listing date fixed as November 14, 2025. Curis Lifesciences IPO price band is set at ₹120.00 to ₹128.00 per share. The lot size for an application is 1,000. The minimum amount of investment required by an individual investor (retail) is ₹2,56,000.00 (2,000 shares) (based on upper price). The minimum lot size investment for HNI is 3 lots (3,000 shares), amounting to ₹3,84,000.

Curis Lifesciences Raises ₹7.79 Crore from Anchor Investors

Ahead of the IPO, Curis Lifesciences raised ₹7.79 crore from six anchor investors by allocating 6,09,000 shares at ₹128 each. Key investors included Sanshi Fund-I, Maiq Growth Scheme Long Only, Strategic Sixth Sense Capital Fund, Viney Growth Fund, Zeta Global Funds, and Moneywise Financial Services Pvt. Ltd.

What’s Ahead for Curis Lifesciences IPO?

Curis Lifesciences IPO has entered its last day of bidding. The Curis Lifesciences IPO subscription status shows that the IPO is witnessing strong investor demand across categories. With an overall subscription status of 16.45 times, investors will now hope for a successful share allotment and a stellar listing afterwards.

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations